Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Gisbert

Showing results (21-30 of 317) with videos related to

Pageof 32
Sort By:
Alimentary Pharmacology & Therapeutics|September 17, 2011
Review article: common misconceptions in the management of Helicobacter pylori-associated gastric MALT-lymphomaJ P Gisbert, X Calvet
Alimentary Pharmacology & Therapeutics|September 13, 2012
Letter: real-life management of new onset ulcerative colitis and proctitisE Domènech, J P Gisbert
Medicina Clinica|May 3, 2001
[Helicobacter pylori eradication: comments from the consensus]F Gomollón, J P Gisbert
Hepato-Gastroenterology|January 30, 2002
Helicobacter pylori infection and precancerous lesions of the stomachJ Valle, J P Gisbert
Alimentary Pharmacology & Therapeutics|December 2, 2011
Review article: rifabutin in the treatment of refractory Helicobacter pylori infectionJ P Gisbert, X Calvet
Alimentary Pharmacology & Therapeutics|April 19, 2017
Editorial: accumulating data about ustekinumab in refractory Crohn's disease in real world experienceS Khorrami, J P Gisbert
Alimentary Pharmacology & Therapeutics|August 7, 2012
Letter: anti-TNFs and psoriasis--friends or foes?I Guerra, J P Gisbert
Alimentary Pharmacology & Therapeutics|April 18, 2013
Letter: dry blood spots for anti-TNF treatment monitoring in IBD--authors' replyM Chaparro, J P Gisbert
Alimentary Pharmacology & Therapeutics|December 5, 2012
Letter: should colectomy be the end-point to evaluate the effectiveness of drug therapies in severe ulcerative colitis?E Domènech, J P Gisbert
Alimentary Pharmacology & Therapeutics|June 7, 2014
Letter: Limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohn's diseaseM Chaparro, J P Gisbert
Pageof 32

Showing results (21-30 of 317) with videos related to

Sort By:
Pageof 32
Alimentary Pharmacology & Therapeutics|September 17, 2011
Review article: common misconceptions in the management of Helicobacter pylori-associated gastric MALT-lymphomaJ P Gisbert, X Calvet
Alimentary Pharmacology & Therapeutics|September 13, 2012
Letter: real-life management of new onset ulcerative colitis and proctitisE Domènech, J P Gisbert
Medicina Clinica|May 3, 2001
[Helicobacter pylori eradication: comments from the consensus]F Gomollón, J P Gisbert
Hepato-Gastroenterology|January 30, 2002
Helicobacter pylori infection and precancerous lesions of the stomachJ Valle, J P Gisbert
Alimentary Pharmacology & Therapeutics|December 2, 2011
Review article: rifabutin in the treatment of refractory Helicobacter pylori infectionJ P Gisbert, X Calvet
Alimentary Pharmacology & Therapeutics|April 19, 2017
Editorial: accumulating data about ustekinumab in refractory Crohn's disease in real world experienceS Khorrami, J P Gisbert
Alimentary Pharmacology & Therapeutics|August 7, 2012
Letter: anti-TNFs and psoriasis--friends or foes?I Guerra, J P Gisbert
Alimentary Pharmacology & Therapeutics|April 18, 2013
Letter: dry blood spots for anti-TNF treatment monitoring in IBD--authors' replyM Chaparro, J P Gisbert
Alimentary Pharmacology & Therapeutics|December 5, 2012
Letter: should colectomy be the end-point to evaluate the effectiveness of drug therapies in severe ulcerative colitis?E Domènech, J P Gisbert
Alimentary Pharmacology & Therapeutics|June 7, 2014
Letter: Limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohn's diseaseM Chaparro, J P Gisbert
Pageof 32